BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The Company's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Laboratories & Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:BGMD
- CUSIP: 08861T10
- Web: www.bg-medicine.com
- 50 Day Moving Avg: $0.05
- 200 Day Moving Avg: $0.06
- 52 Week Range: $0.03 - $0.18
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 0.56
- P/E Growth: 0.000
- Annual Revenue: $1.57 million
- Price / Sales: 0.32
- Book Value: ($0.18) per share
- Price / Book: -0.26
- EBIDTA: ($4,390,000.00)
- Net Margins: -311.03%
- Return on Assets: -131.82%
- Average Volume: 5,425 shs.
- Short Ratio: 2.66
Frequently Asked Questions for BG Medicine (NASDAQ:BGMD)
What is BG Medicine's stock symbol?
BG Medicine trades on the NASDAQ under the ticker symbol "BGMD."
How were BG Medicine's earnings last quarter?
BG Medicine, Inc. (NASDAQ:BGMD) posted its earnings results on Tuesday, November, 17th. The company reported ($0.27) EPS for the quarter. The company had revenue of $334 million for the quarter, compared to analysts' expectations of $695 million. View BG Medicine's Earnings History.
Who are some of BG Medicine's key competitors?
Some companies that are related to BG Medicine include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), ConvaTec Group PLC (CTEC), Health Net (HNT), Catalent (CTLT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), Cotiviti Holdings (COTV), WuXi PharmaTech (Cayman) (WX) and Enerplus Corp (ERF).
Who are BG Medicine's key executives?
BG Medicine's management team includes the folowing people:
- Harry W. Wilcox III, Chairman of the Board
- Paul R. Sohmer M.D., President, Chief Executive Officer, Director
- Stephen P. Hall, Chief Financial Officer, Executive Vice President, Treasurer
- Aram Adourian Ph.D., Senior Vice President, Chief Scientific Officer
- Jeffrey R. Luber J.D., Independent Director
- James F. O'Connor CPA, Independent Director
- Stelios B. Papadopoulos Ph.D., Independent Director
How do I buy BG Medicine stock?
Shares of BG Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BG Medicine's stock price today?
MarketBeat Community Rating for BG Medicine (NASDAQ BGMD)MarketBeat's community ratings are surveys of what our community members think about BG Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of BG Medicine stock can currently be purchased for approximately $0.05.
Consensus Ratings for BG Medicine (NASDAQ:BGMD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for BG Medicine (NASDAQ:BGMD)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for BG Medicine (NASDAQ:BGMD)Earnings History by Quarter for BG Medicine (NASDAQ BGMD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/17/2015||Q315||($0.27)||$695.00 million||$334.00 million||View||N/A|
|5/14/2015||Q115||($0.03)||($0.04)||$1.60 million||$0.44 million||View||Listen|
|8/14/2014||Q214||($0.06)||($0.06)||$1.40 million||$2.20 million||View||N/A|
|5/14/2014||Q114||($0.08)||($0.08)||$1.30 million||$0.74 million||View||N/A|
|3/20/2014||Q413||($0.12)||($0.06)||$1.10 million||$1.15 million||View||N/A|
|8/8/2013||Q2 2013||($0.20)||($0.18)||$1.27 million||$1.00 million||View||N/A|
|5/9/2013||Q1 2013||($0.27)||($0.21)||$1.16 million||$0.89 million||View||N/A|
Earnings Estimates for BG Medicine (NASDAQ:BGMD)
Current Year EPS Consensus Estimate: $-0.100 EPS
Next Year EPS Consensus Estimate: $0.080 EPS
Dividend History for BG Medicine (NASDAQ:BGMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BG Medicine (NASDAQ:BGMD)Insider Trades by Quarter for BG Medicine (NASDAQ:BGMD)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/9/2015||Noubar Afeyan||Director||Sell||46,438||$0.56||$26,005.28|| |
|12/11/2014||Edwin M Kania Jr||Major Shareholder||Sell||634,390||$0.32||$203,004.80|| |
|1/30/2013||Stelios Papadopoulos||Director||Buy||250,000||$2.00||$500,000.00|| |
|11/19/2012||Brian S Posner||Director||Buy||10,000||$1.17||$11,700.00|| |
|11/15/2012||Stephane Bancel||Chairman||Buy||100,000||$1.26||$126,000.00|| |
Headline Trends for BG Medicine (NASDAQ:BGMD)
Latest Headlines for BG Medicine (NASDAQ:BGMD)
|Signal Genetics (MGEN) & BG Medicine (NASDAQ:BGMD) Head to Head Review|
www.americanbankingnews.com - August 3 at 7:58 AM
|BG Medicine (NASDAQ:BGMD) & Signal Genetics (MGEN) Head to Head Analysis|
www.americanbankingnews.com - August 2 at 10:14 AM
|Contrasting BG Medicine (BGMD) and Signal Genetics (MGEN)|
www.americanbankingnews.com - July 29 at 12:35 PM
|Comparing BG Medicine (NASDAQ:BGMD) & Signal Genetics (MGEN)|
www.americanbankingnews.com - July 26 at 2:27 PM
|Comparing Signal Genetics (MGEN) & BG Medicine (NASDAQ:BGMD)|
www.americanbankingnews.com - July 26 at 12:26 AM
|Signal Genetics (MGEN) versus BG Medicine (BGMD) Financial Survey|
www.americanbankingnews.com - July 24 at 9:25 AM
|Head-To-Head Contrast: Miragen Therapeutics (MGEN) & BG Medicine (BGMD)|
www.americanbankingnews.com - July 23 at 4:21 PM
|BG Medicine (NASDAQ:BGMD) versus Signal Genetics (MGEN) Head-To-Head Review|
www.americanbankingnews.com - July 7 at 8:08 AM
|Critical Contrast: PAREXEL International Corporation (PRXL) and BG Medicine (BGMD)|
www.americanbankingnews.com - June 16 at 8:25 AM
|BG MEDICINE, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - April 4 at 5:02 PM
|BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events|
biz.yahoo.com - March 31 at 5:06 PM
|BG Medicine, Inc. (BGMD)|
finance.yahoo.com - February 21 at 9:51 AM
|BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - February 4 at 5:05 PM
|BG MEDICINE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - December 23 at 7:58 AM
|BG MEDICINE, INC. Financials|
finance.yahoo.com - December 8 at 1:18 PM
|BG MEDICINE, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibit|
biz.yahoo.com - December 4 at 5:04 PM
|BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - November 30 at 7:50 AM
|BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;|
biz.yahoo.com - November 23 at 4:25 PM
|BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - November 20 at 5:02 PM
|Edited Transcript of BGMD earnings conference call or presentation 17-Nov-15 1:30pm GMT|
finance.yahoo.com - November 17 at 1:57 PM
|BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statemen|
biz.yahoo.com - November 17 at 8:02 AM
|BG MEDICINE, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 16 at 5:16 PM
|BG Medicine Due Diligence Report: Quietly Making Headway - Broad Street Alerts|
finance.yahoo.com - November 5 at 8:33 AM
BG Medicine (BGMD) Chart for Saturday, September, 23, 2017